Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC — Stella

Home/Immune-Mediated Hepatitis/Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

View on ClinicalTrials.gov

Recruiting

Back to Immune-Mediated Hepatitis trials

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

Key details

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Enrollment target

~60 participants

Started

August 2022

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.